Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-18. (Canceled)

19. (Currently amended) A method comprising:

a) contacting a polypeptide that comprises ~~the~~ an amino acid sequence having at least 95% homology with the amino acid sequence of SEQ ID NO:[[12]] 2, or a cell expressing a polypeptide that comprises ~~the~~ an amino acid sequence having at least 95% homology with the amino acid sequence of SEQ ID NO:[[12]] 2 with a test compound; and

b) determining whether the polypeptide binds to the test compound.

20.-53. (Canceled)

54. (Previously presented) The method of claim 19 wherein the contacting is *in vitro*.

55. (Previously presented) The method of claim 19 wherein the contacting comprises contacting a cell expressing the polypeptide.

56. (Previously presented) The method of claim 19 wherein the determining comprises directly detecting test compound/polypeptide binding.

57. (Previously presented) The method of claim 19 wherein the determining comprises a competition binding assay.

58. (Canceled)

59. (Previously presented) The method of claim 19 wherein the test compound comprises a peptide.

60. (Previously presented) The method of claim 19 wherein the test compound is fluorescently labeled.

61. (Previously presented) The method of claim 19 wherein the test compound is a member of biological library.

62. (Previously presented) The method of claim 19 wherein the test compound is attached to a bead.

63. (Currently amended) A method of evaluating the effect of interaction between a test compound and a polypeptide that comprises ~~the~~ an amino acid sequence having at least 95% homology with the amino acid sequence of SEQ ID NO:[[12]] 2, the method comprising:

a) contacting a polypeptide ~~that comprises the~~ comprising an amino acid sequence having at least 95% homology with the amino acid sequence of SEQ ID NO:[[12]] 2, or a cell expressing a polypeptide that comprises ~~the~~ an amino acid sequence having at least 95% homology with the amino acid sequence of SEQ ID NO:[[12]]2 with a test compound; and

b) ~~evaluating~~ determining hydrolysis of the test compound, wherein hydrolysis of the test compound indicates an effect of the test compound on the polypeptide, to thereby evaluate the effect of the interaction between the test compound and the polypeptide.

64. (Canceled)

65. (Previously presented) The method of claim 19 wherein the test compound comprises a peptoid.

66. (Previously presented) The method of claim 19 wherein the test compound comprises a peptidomimetic.

67. (Previously presented) The method of claim 19 wherein the test compound is selected from the group consisting of: L-1-Chloro-3-tosylamido-4-phenyl-2-butanone, Soybean inhibitor, benzamidine, p-Nitrophenyl-p-guanidino benzoate, Tosyl-L-lysine chloromethyl ketone, and Tosyl-L-arginine chloromethyl ketone.

68. (Previously presented) The method of claim 19 wherein the test compound is a protein.

Please add the following new claims:

69. (New) A method comprising:

a) contacting a polypeptide that comprises an amino acid sequence of SEQ ID NO:2 or which differs by at least one but less than 5 amino acid residues from the amino acid sequence of SEQ ID NO:2, or a cell expressing a polypeptide that comprises an amino acid sequence of SEQ ID NO:2 or which differs by at least one but less than 5 amino acid residues from the amino acid sequence of SEQ ID NO:2, with a test compound; and

b) determining whether the polypeptide binds to the test compound.

70. (New) The method of claim 69 wherein the contacting is *in vitro*.

71. (New) The method of claim 69 wherein the contacting comprises contacting a cell expressing the polypeptide.

72. (New) The method of claim 69 wherein the determining comprises directly detecting test compound/polypeptide binding.

73. (New) The method of claim 69, wherein the determining comprises a competition binding assay.

74. (New) The method of claim 69, wherein the test compound comprises a peptide.

75. (New) The method of claim 69, wherein the test compound is fluorescently labeled.

76. (New) The method of claim 69, wherein the test compound is a member of biological library.

77. (New) The method of claim 69, wherein the test compound is attached to a bead.

78. (New) A method of evaluating the effect of interaction between a test compound and a polypeptide that comprises an amino acid sequence of SEQ ID NO: 2 or which differs from the amino acid sequence of SEQ ID NO:2 by at least one but less than 5 amino acid residues, the method comprising:

a) contacting a polypeptide comprising an amino acid sequence of SEQ ID NO:2 or which differs by at least one but less than 5 amino acids from the amino acid sequence of SEQ ID NO:2, or a cell expressing a polypeptide that comprises an amino acid sequence of SEQ ID NO:2 or which differs by at least one but less than 5 amino acids from the amino acid sequence of SEQ ID NO:2 with a test compound; and

b) determining hydrolysis of the test compound, wherein hydrolysis of the test compound indicates an effect of the test compound on the polypeptide, to thereby evaluate the effect of the interaction between the test compound and the polypeptide.

79. (New) The method of claim 69, wherein the test compound comprises a peptoid.

80. (New) The method of claim 69, wherein the test compound comprises a peptidomimetic.

81. (New) The method of claim 69, wherein the test compound is selected from the group consisting of: L-1-Chloro-3-tosylamido-4-phenyl-2-butanone, Soybean inhibitor, benzamidine, p-Nitrophenyl-p-guanidino benzoate, Tosyl-L-lysine chloromethyl ketone, and Tosyl-L-arginine chloromethyl ketone.

82. (New) The method of claim 69, wherein the test compound is a protein.